In a significant advancement for clinical endocrinology, Revvity has secured US Food and Drug Administration (FDA) clearance for its total testosterone automated chemiluminescence immunoassay (ChLIA). Facilitated through its subsidiary, Immunodiagnostic Systems (IDS), this regulatory milestone completes a comprehensive, fully integrated diagnostic suite designed to streamline the assessment of androgen-related disorders. By consolidating total testosterone, free testosterone, and sex hormone-binding globulin (SHBG) testing onto a single, automated platform, Revvity is poised to redefine the workflow efficiency of diagnostic laboratories across the United States.
The Evolution of Hypogonadism Diagnostics
Male hypogonadism, a clinical syndrome resulting from the failure of the testes to produce adequate levels of testosterone, presents a complex diagnostic challenge. Symptoms are often non-specific, including fatigue, depression, reduced libido, and metabolic shifts, necessitating precise biochemical confirmation. Historically, the clinical gold standard for measuring free testosterone—the biologically active form of the hormone—has been equilibrium dialysis followed by liquid chromatography-mass spectrometry (ED-LC/MS).
While ED-LC/MS is highly accurate, it is notorious for being labor-intensive, requiring specialized technical expertise, complex mathematical modeling, and significant turnaround times. The inherent lack of standardization and the operational burden of these legacy methods have long hindered the ability of smaller and mid-sized laboratories to provide rapid, reliable results. Revvity’s new automated ChLIA platform directly addresses these pain points, offering a modernized, high-throughput alternative that maintains rigorous clinical standards without the logistical bottlenecks of traditional mass spectrometry.
Chronology of Innovation: Building an Integrated Portfolio
Revvity’s recent FDA clearance represents the culmination of a multi-year strategic expansion of its endocrine testing portfolio. The journey toward this integrated diagnostic suite has been marked by a consistent focus on automation and accessibility:
- Foundation Phase: IDS, now a cornerstone of the Revvity diagnostic ecosystem, established a reputation for high-quality, automated immunoassay platforms.
- Expansion of Reproductive Markers: Recognizing the need for a holistic view of endocrine health, Revvity successfully brought assays for prolactin, 17-OH progesterone (17-OHP), and androstenedione through the regulatory pipeline.
- The SHBG and Free Testosterone Milestone: Prior to the recent clearance, Revvity achieved regulatory success with its FDA-cleared tests for free testosterone and SHBG, laying the groundwork for a cohesive, automated diagnostic pathway.
- Current Breakthrough (May 2026): The FDA clearance of the total testosterone assay completes the trinity of primary markers. This enables laboratories to run a full profile on a single, random-access automation platform, marking a paradigm shift in how clinicians approach the workup of androgen-related conditions.
- Complementary Technological Growth: This achievement follows closely on the heels of the company’s April 2025 success, where the FDA granted approval for the Auto-Pure 2400 liquid handling platform, demonstrating a broader corporate commitment to refining laboratory workflows across multiple disciplines, including infectious disease testing (T-SPOT.TB).
Technical Implications: Eliminating Operational Hurdles
The core value proposition of Revvity’s new assay lies in its ability to eliminate the "fragmented diagnostic model." In a standard laboratory setting, a physician suspecting hypogonadism might order a battery of tests that are traditionally routed through different analyzers or outsourced to reference labs. This fragmentation leads to delays in diagnosis and patient frustration.
By integrating the total testosterone assay onto the IDS automation platforms, Revvity offers a seamless "sample-to-result" experience. Key technical advantages include:
- Workflow Consolidation: Laboratories can process total testosterone, free testosterone, and SHBG on the same instrument, reducing the physical footprint of testing and minimizing sample transfer errors.
- Standardization: Automation removes the human variability inherent in manual calculations or complex mass spectrometry sample preparation, ensuring greater reproducibility across different laboratory environments.
- Speed to Diagnosis: By removing the requirement for ED-LC/MS, laboratories can provide results within the same shift, significantly reducing the "wait time" for patients concerned about endocrine health.
- Operational Scalability: The random-access nature of the IDS platform allows laboratories to manage fluctuating test volumes without the need to reconfigure their entire testing architecture.
Official Perspectives and Industry Impact
The reception of this clearance from the scientific and industrial community has been positive, particularly among laboratory directors who have long struggled with the operational demands of older testing methods.
Arvind Kothandaraman, Vice-President and General Manager of Euroimmun North America—a Revvity company—emphasized the strategic importance of this development. "Adding the total testosterone assay to our automated ChLIA platform transforms the offering to a wholly integrated solution that supports diagnostic testing for androgen-related conditions in both men and women," Kothandaraman stated. He further noted that this clearance is a testament to the company’s broader mission: "This clearance demonstrates our commitment to continued expansion of our portfolio to aid in the timely diagnosis of endocrine disorders."
Industry analysts suggest that Revvity’s strategy is well-timed. As the global population ages, the prevalence of conditions linked to hormonal imbalances—such as metabolic syndrome and late-onset hypogonadism—is on the rise. Diagnostic providers who can offer high-quality, automated solutions are likely to capture a significant share of the market as hospitals and independent laboratories seek to replace aging, manual systems with modern, consolidated technologies.
Broader Clinical Implications: Beyond Male Hypogonadism
While the primary headline focuses on male hypogonadism, the clinical implications of this integrated portfolio extend to a variety of endocrine disorders. Testosterone and SHBG levels are critical markers in the assessment of Polycystic Ovary Syndrome (PCOS), hirsutism, and various adrenal conditions in women.
The ability to test these markers with high sensitivity and precision in a high-throughput format allows for more nuanced clinical decision-making. Physicians can now monitor hormone levels with greater frequency and confidence, allowing for more precise titration of hormone replacement therapies (HRT) or other endocrine-modulating treatments.
Furthermore, by reducing the cost and technical barrier to entry for these tests, Revvity is democratizing access to high-tier diagnostic capabilities. Smaller regional hospitals, which previously might have had to send samples to large, distant reference labs, may now be able to perform these assays in-house, keeping patient care centralized and more efficient.
Conclusion: The Path Forward
Revvity’s successful navigation of the FDA regulatory process for its total testosterone assay marks a significant milestone in the company’s history. By successfully transitioning from niche diagnostic testing to a comprehensive, automated, and integrated laboratory ecosystem, Revvity has positioned itself as a critical partner for the modern clinical laboratory.
As the company continues to serve the pharmaceutical, biotech, academic, and governmental sectors across more than 160 countries, this new offering serves as a model for how legacy diagnostic challenges can be solved through thoughtful engineering and regulatory foresight. With the integration of the total testosterone assay, the landscape of endocrine diagnostics is becoming clearer, faster, and more reliable, ultimately leading to better outcomes for the millions of patients who rely on accurate hormone monitoring for their long-term health and well-being.
The future of the laboratory is clearly one of integration and automation, and with this latest FDA clearance, Revvity has firmly established itself at the forefront of that transition.
About the Author
